Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 46 to 60 of 83 results for atezolizumab

  1. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued [GID-TA10830]

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]

    Technology appraisal guidance
    Discontinued

  3. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued [GID-TA10354]

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

    Discontinued [GID-TA10546]

    Technology appraisal guidance
    Discontinued

  5. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued [GID-TA11522]

    Technology appraisal guidance
    Discontinued

  6. Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

    Discontinued [GID-TA10543]

    Technology appraisal guidance
    Discontinued

  7. Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]

    Discontinued [GID-TA10531]

    Technology appraisal guidance
    Discontinued

  8. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued [GID-TA10202]

    Technology appraisal guidance
    Discontinued

  9. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued [GID-TA11000]

    Technology appraisal guidance
    Discontinued

  10. Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495]

    Discontinued [GID-TA10395]

    Technology appraisal guidance
    Discontinued

  11. Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)

    Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.

    Technology appraisal guidance
    Published
    17 August 2022
    View recommendations

    Sections for TA819

  12. Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

    Discontinued [GID-TA10574]

    Technology appraisal guidance
    Discontinued

  13. Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)

    Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    14 June 2023
    View recommendations

    Sections for TA898

  14. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812

      Status ...

    Health technology evaluations
    Topic selection